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ECOG Baseline Visit 1 Visit 2 Visit 3 Visit 4
0 12.3 14.7 13.6 13.8 12.7
1 16.4 15.5 14.6 14.1 15.2
2 17.6 17.8 16.3 16.1 16.9
3 n/a 22.4 22.8 19.6 20.7
p-value 0.0002 0.0017 <0.0001 0.0048 0.0011
N 132 98 77 66 49
 
Conclusions: Retrospective analysis of trial data suggests that PSALC 
is a reliable, valid, and responsive scale for measuring SCLC symp-
toms. If feasible in SCLC population, a prospective validation study 
could be used to further evaluate the validity of this symptom scale.
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Background: Post-translational modiﬁcations in the tails of nucleoso-
mal core histones are emerging as important signalling processes con-
trolling a wide variety of functions. Indeed they play a crucial role in 
chromatin packaging, gene expression and genome stability. Therefore, 
perturbation of this epigenetic information is likely to be involved in 
the development of cancer. Although some studies identiﬁed an altered 
activity of histone-modifying enzymes in tumors, little is known about 
the post-translational modiﬁcations of histones in these malignancies. 
Methods: By using immunohistochemistry, we studied the pattern of 
histone H4 modiﬁcations in a series of 100 primary non small cell lung 
tumors comprising 51 squamous carcinoma and 49 adenocarcinoma. 
Speciﬁc antibodies recognizing acetylated histone H4 at positions K5, 
K8 and K16 and trimethylated histone H4 at position K20 were used 
on frozen tissue sections with an automated immunostainer Ventana in 
order to standardize the staining. Normal lung epithelial cells (al-
veolar and bronchial basal cells) were taken as internal controls and 
their score used for determination of the cut off score to discriminate 
between positive (score at least equal to normal) and negative (score 
lower than normal) cases. 
Results: Our data show that, as compared to normal lung, lysines 5 
and 8 of histone H4 are hyperacetylated in 48% and 40% of all tumors 
respectively, more frequently in squamous carcinoma than in adenocar-
cinoma (p=0.009 and p=0.0002 respectively). In contrast, acetylation 
at Lys16 and trimethylation at Lys20 are lost in 52% and 47% of the 
tumors respectively. Across histological types loss of trimethylation at 
Lys20 is more frequent in squamous carcinoma than in adenocarcinoma 
(p=0.0002), is associated with advanced stage (p=0.018) and nodal 
metastasis (p=0.01) and correlates with a poor survival among stade 
I (p=0.026). Importantly, in adenocarcinoma, loss of trimethylation 
at Lys20 is associated with advanced stage (p=0.006) and correlates 
with a poor survival among stage I-II (p=0.0001) and N0 versus N1-2 
(p=0.013) tumors. Furthermore, the double loss of acetylation at Lys16 
and trimethylation at Lys20 is associated with a shorter survival in 
these patients as compared to the presence of either one or none of 
these alterations. 
Conclusion: These data provide the ﬁrst evidence of a global aberrant 
pattern of histone H4 modiﬁcation in lung tumors with hyperacety-
lation of Lysines 5 and 8 and loss of acetylation of lysine 16 and of 
trimethylation of Lysine 20. The frequent loss of lysine 20 trimethyl-
ation in squamous carcinoma, independently of the stage, suggests that 
it could be an early event in the carcinogenesis of this tumor type. In 
contrast, loss of lysine 20 trimethylation is less frequent in adenocar-
cinoma but correlates with a poor prognosis suggesting a role in the 
progression of these tumors.
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Background: In the development of cancer, a series of tumor suppres-
sor genes is inactivated by point mutation and chromosomal deletion. 
Aberrant methylation of CpG islands has recently been shown to serve 
as an alternative way of inactivating such genes in cancer. Methylation 
of cytosine residues in CpG dinucleotides is an extremely important 
epigenetic modiﬁcation of the eukaryotic genome that affects vari-
ous cell processes. Methylation is known to play an important role in 
neoplasia by inactivating tumor suppressor genes such as Rb, p16, and 
estrogen receptor. In this study we used CpG island ampliﬁcation and 
suppression subtractive hybridization to identify the aberrant methyla-
tion of CpG islands in A/J mouse lung adenoma, in order to clarify 
whether a hypermethylated homologue gene exists in human pulmo-
nary adenocarcinoma.
Methods: NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone)-
induced A/J mouse lung adenoma and normal tissue were used in this 
study. The histology of A/J mouse adenoma mimics the early stage of 
human pulmonary adenocarcinoma. The genomic DNA was extracted 
using standard procedures. The PCR-based methylated CpG island am-
pliﬁcation (MCA) technique was used for detection of methylated CpG 
islands. Suppression subtractive hybridization (SSH) and differential 
screening (DS) were used to identify the differentially methylated se-
quence in A/J mouse lung adenoma tissue. For the genes selected after 
SSH and DS analysis, quantitative Real-time PCR was used to check 
their expression level in A/J mouse lung adenoma tissue and normal tis-
sue. Using homoloGene software, human homologue genes were then 
detected. Real-time PCR was also performed to check the expression 
level of these genes in human lung adenocarcinoma and normal lung 
tissue. Bisulﬁte genomic sequencing was done to conﬁrm the methyla-
tion status of these genes in the promotor area.
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Results: After MCA-SSH and DS, 117 clones from a total of 1000 
were selected for sequence analysis. Four genes were identiﬁed in the 
DNA fragments from 117 clones from A/J mouse lung tumor tissue. 
These were KIF21A (kinesin family member 21A), Samd14 (sterile 
alpha motif domain containing 14), EG436235 (similar to regulator of 
G-protein signal 3) and Vwa1 (von Willebrand factor A domain con-
taining 1). Among these four genes, two gene fragments had a genomic 
region that met the criteria for a CpG island. RT-PCR showed differ-
ences in expression level between A/J mouse normal lung tissue and 
lung adenoma tissue for the KIF21A (p<0.005), Samd14 (p=0.005) and 
EG436235 (p<0.01) genes. Further study of the human homologues 
of KIF21A (p<0.01) and Samd14 (p<0.002) showed that they were 
expressed in normal lung tissue but markedly down-regulated in lung 
adenocarcinoma tissue. Bisulﬁte sequencing revealed that the prom-
tor region of Samd14 in human lung adenocarcinoma was methylated 
more frequently than that of its normal counterpart.
Conclusions: The expression level of the KIF21A (location: 12q12) 
and Samd14 (location: 17q21.33) genes is down regulated in human 
pulmonary adenocarcinoma tissue. The methylation frequency of the 
Samd14 gene in the promotor region is higher in human pulmonary 
adenocarcinoma than in normal lung tissue. These data suggest that 
promotor methylation of these genes is a speciﬁc event in pulmonary 
adenocarcinogenesis, and that their down-regulation may be function-
ally associated with malignant progression of lung adenocarcinoma
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Introduction: A novel approach has been developed for the prediction 
of major NSCLC classes and the prediction of patient outcome based 
on gene expression. To achieve this, bronchial and lung biopsies taken 
at the time of diagnosis were processed on a high-sensitivity microar-
ray platform.
Methods: Microarray proﬁling was performed using the NovaChip® 
array platform. Samples were lung and bronchoscopic biopsies from 61 
NSCLC patients (24 adenocarcinoma, 22 squamous cell carcinoma, 15 
non-otherwise speciﬁable NSCLC), and samples from 18 patients non-
malignant inﬂammatory lung disease (7 chronic bronchitis, 7 interstitial 
lung disease, 4 sarcoidosis). NSCLC class prediction was performed 
using multivariate supervised between-group analysis (BGA). Predic-
tion accuracy was assessed by leave-one-out crossvalidation. Prediction 
of clinical outcome was based on Cox regression and a metagene-based 
approach followed by Kaplan-Meier analyses. The robustness of the 
identiﬁed metagene was tested by two-level cross-validation.
Results: NSCLC class prediction - The two major NSCLC classes 
were efﬁciently separated despite the proportion of tumor tissue of the 
biopsies was low in 17 samples (prediction accuracy 96%). In 19 sam-
ples the pathologist could not identify tumor cells (diagnosis was made 
with subsequent histology). In these samples the prediction accuracy 
was 43%. Roughly 70% of discriminative genes matched with previous 
reports, which validated the presence of tumor signals (squamous cell 
carcinoma: e.g. cytokeratins; adenocarcinoma: e.g. pulmonary-surfac-
tant proteins).
Clinical outcome prediction - NSCLC samples were scored using a 
metagene (Figure 1, left panel). This prognostic metagene was able 
to differentiate “high” and “low” risk outcomes within each of four 
NSCLC tumor stages (Figure 1, right panel). There was a signiﬁcant 
gain of outcome prediction when using this metagene compared with 
the staging information alone (p<0.001). Grading, age and sex were not 
associated with outcome.
Figure 1. Prediction of survival based on a prognostic metagene. The left 
panel shows the correlation between survival and metagene scores. Only 3 
out of 14 patients with a metagene score >75th percentile survived >1 year. 
The right panel shows Kaplan-Meier curves of the four NSCLC stages that are 
differentiated further into two subclasses based on the metagene scores. 
Conclusion: Our microarray-based approach shows that it is possible 
to use small lung or bronchial biopsies obtained by endoscopy to help 
assessing tumor class membership and to predict clinical outcome. 
Thus, this approach could be particularly useful for those NSCLC 
patients who do undergo neither surgery nor CT-guided biopsy proce-
dures. Microarray results were complementary to histopathology.
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Background: Activating epidermal growth factor receptor (EGFR) 
mutations in NSCLC tumors are associated with rapid and sustained 
clinical response to EGFR tyrosine kinase inhibitors (TKIs). Due to 
tumor heterogeneity, identiﬁcation of EGFR mutations using conven-
tional DNA sequencing approaches can be problematic. Tumor-speciﬁc 
mutations such as KRAS have been detected in shed tumor DNA in 
patient plasma (Kimura, Ann N Y Acad Sci, 2004), and the ability 
to detect EGFR mutations in patient plasma would have potentially 
signiﬁcant clinical utility. Here we describe the performance of an al-
lele-speciﬁc real-time PCR system utilizing Scorpion primers (provided 
by DxS, UK) to detect EGFR mutations in tumor tissue and plasma.
Methods: The sensitivity of this technique in terms of the ratio of 
mutant-to-wild-type genomic DNA and the minimum amount of DNA 
required for detection was determined using a dilution experiment. 
Genomic DNA from lung cancer cell lines containing either the exon 
21 L858R point mutation or the exon 19 E746-750 deletion was mixed 
with wild-type genomic DNA at ratios ranging from 1:2 to 1:10,000. 
